- Previous Close
5.56 - Open
5.50 - Bid 5.36 x 300
- Ask 5.52 x 100
- Day's Range
5.33 - 5.85 - 52 Week Range
4.82 - 27.72 - Volume
161,719 - Avg. Volume
561,211 - Market Cap (intraday)
256.376M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-1.66 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
53.70
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
www.silence-therapeutics.com109
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: SLN
View More
Performance Overview: SLN
Trailing total returns as of 2025-01-22, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLN
View MoreValuation Measures
Market Cap
212.47M
Enterprise Value
53.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.97
Price/Book (mrq)
2.20
Enterprise Value/Revenue
2.67
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-224.01%
Return on Assets (ttm)
-21.54%
Return on Equity (ttm)
-64.28%
Revenue (ttm)
17.9M
Net Income Avi to Common (ttm)
-40.1M
Diluted EPS (ttm)
-1.66
Balance Sheet and Cash Flow
Total Cash (mrq)
149.59M
Total Debt/Equity (mrq)
0.16%
Levered Free Cash Flow (ttm)
-14.3M
Research Analysis: SLN
View MoreCompany Insights: SLN
SLN does not have Company Insights